AIDS is a globalized infectious disease. In 2014, UNAIDS launched a global project of
“90-90-90” to end the HIV epidemic by 2030. The second and third 90 require 90% of HIV-1 infected
individuals receiving antiretroviral therapy (ART) and durable virological suppression. However,
wide use of ART will greatly increase the emergence and spreading of HIV drug resistance and
current HIV drug resistance test (DRT) assays in China are seriously lagging behind, hindering to
achieve virological suppression. Therefore, recommending an appropriate HIV DRT method is critical
for HIV routine surveillance and prevention in China. In this review, we summarized the current
existing HIV drug resistance genotypic testing methods around the world and discussed the advantages
and disadvantages of these methods.